Potent androgen antagonists based on carborane as a hydrophobic core structure

Journal of Medicinal Chemistry

Volumn 48, Issue 14, 2005, Pages 4654-4662

  Fujii, Shinya ^a   Goto, Tokuhito ^b   Ohta, Kiminori ^b   Hashimoto, Yuichi ^c   Suzuki, Tomoharu ^d   Ohta, Shigeru ^d   Endo, Yasuyuki ^b  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 NITROPHENYL) 1,12 DICARBADODECABORANE 1 CARBOXYLIC ACID; 1 HYDROXYMETHYL 12 (3 NITROPHENYL) 1,12 DICARBADODECABORANE; ANTIANDROGEN; BORON DERIVATIVE; CARBON; CARBORANE DERIVATIVE; HYDROXYFLUTAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CELL LINE; CELL STRAIN 3T3; CELL STRAIN SC 3; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; GENETIC TRANSFECTION; GROWTH INHIBITION; HYDROPHOBICITY; MOUSE; NONHUMAN; PLASMID; REPORTER GENE; THERMOSTABILITY;

ANDROGEN ANTAGONISTS; ANIMALS; BINDING, COMPETITIVE; BORANES; BORON COMPOUNDS; CELL LINE, TUMOR; CELL PROLIFERATION; GENES, REPORTER; HUMANS; MICE; NIH 3T3 CELLS; RADIOLIGAND ASSAY; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC;

EID: 22244438605     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050115j     Document Type: Article

References (34)

1. For recent reviews on medicinal applications, see: Hawthorne, M. F. The role of chemistry in the development of boron neutron capture therapy of cancer. Angew. Chem. Int. Ed. Engl. 1993, 32, 950-984.
2. Soloway, A. H.; Tjarks, W.; Barnum, J. G. The chemistry of neutron capture therapy. Chem. Rev. 1998, 98, 1515-1562.
3. Fauchere, J. L.; Do, K. Q.; Jow, P. Y. C.; Hansch, C. Unusually strong lipophilicity of 'fat' or 'super' amino acids, including a new reference value for glycine. Experientia 1980, 36, 1203-1204.
4. Yamamoto, K.; Endo, Y. Utility of boron clusters for drug design. Hansch-Fujita hydrophobic parameters π of dicarba-closo-dodecaboranyl groups. Bioorg. Med. Chem. Lett. 2001, 11, 2389-2392.
5. Endo, Y.; Yamamoto, K.; Kagechika, H. Utility of boron clusters for drug design. Relation between estrogen receptor binding affinity and hydrophobicity of phenols bearing various types of carboranyl groups. Bioorg. Med. Chem. Lett. 2003, 13, 4089-4092.
6. Endo, Y.; Iijima, T.; Yamakoshi, Y.; Yamaguchi, M.; Fukasawa, H.; Shudo, K. Potent estrogenic agonists bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore. J. Med. Chem. 1999, 42, 1501-1504.
7. Endo, Y.; Iijima, T.; Yamakoshi, Y.; Kubo, A.; Itai, A. Structure-activity study of estrogenic agonists bearing dicarba-closo- dodecaborane. Effect of geometry and separation distance of hydroxyl groups at the ends of molecules. Bioorg. Med. Chem. Lett. 1999, 9, 3313-3318.
8. Endo, Y.; Iijima, T.; Yamakoshi, Y.; Fukasawa, H.; Miyaura, C.; Kubo, A.; Itai, A. Potent estrogen agonists based on carborane as a hydrophobic skeletal structure: A new medicinal application of boron clusters. Chem. Biol. 2001, 8, 341-355.
9. Endo, Y.; Yoshimi, T.; Iijima, T.; Yamakoshi, Y. Estrogenic antagonists bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore. Bioorg. Med. Chem. Lett. 1999, 9, 3387-3392.
10. Endo, Y.; Yoshimi, T.; Yamakoshi, Y. New estrogenic antagonists bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore. Chem. Pharm. Bull. 2000, 48, 312-314.
11. Iijima, T.; Endo, Y.; Tsuji, M.; Kawachi, E.; Kagechika, H.; Shudo, K. Dicarba-closo-dodecaboranes as a pharmacophore. Retinoidal antagonists and potential agonists. Chem. Pharm. Bull. 1999, 47, 398-404.
12. Endo, Y.; Iijima, T.; Ohta, K.; Kagechika, H.; Kawachi, E.; Shudo, K. Dicarba-closo-dodecaboranes as a pharmacophore. Novel potent retinoidal agonists. Chem. Pharm. Bull. 1999, 47, 585-587.
13. Endo, Y.; Iijima, T.; Yaguchi, K.; Kawachi, E.; Kagechika, H. Structure-activity study of retinoid agonists bearing substituted dicarba-closo-dodecaborane. Relation between retinoidal activity and conformation of two aromatic nuclei. BioMed. Chem. Lett. 2001, 11, 1307-1311.
14. Endo, Y.; Yaguchi, K.; Kawachi, E.; Kagechika, H. Polymethylcarborane as a novel bioactive moiety: derivatives with potent retinoid antagonistic activity. BioMed. Chem. Lett. 2000, 10, 1733-1736.
15. Neumann, F. In Pharmacology and clinical uses of inhibitors of hormone secretion and action; Furr, B. J. A., Wakeling, A. E., Eds.; Bailliere Tindall: London, 1987; p 132.
16. Mooradian, A. D.; Morley, J. E.; Korenman, S. G. Biological actions of androgens. Endocr. Rev. 1987, 8, 1-28.
17. Zhi, L.; Martinborough, E. Selective androgen receptor modulators (SARMs). Annu. Rep. Med. Chem. 2001, 36, 169-180.
18. Fujii, S.; Hashimoto, Y.; Suzuki, T.; Ohta, S.; Endo, Y. A new class of androgen receptor antagonists bearing carborane in place of a steroidal skeleton. Bioorg. Med. Chem. Lett. 2005, 15, 227-230.
19. Zakharkin, L. I.; Kovredov, A. I. Preparation of 1-aryl-o-, 1-aryl-m-, and 1-aryl-p-carboranes via copper derivatives of o-, m-, and p-carboranes. Izv. Akad. Nauk SSSR, Ser. Khim. 1974, 740.
20. Hawthorne, M. F.; Berry, T. E.; Wegner, P. A. The electronic properties of the 1,2- and 1,7-dicarba-closo-dodecaborane(12) groups bonded at carbon. J. Am. Chem. Soc. 1965, 87, 4746-4750.
21. Endo, Y.; Taoda, Y. Electronic Effects of Dicarba-closo-dodecaboranes. Friedel-Crafts Acylation of 1-Phenyl-closo-dodecaboranes. Tetrahedron Lett. 1999, 40, 9073-9076.
22. Zakharkin, L. I.; Zhigareva, G. G. Preparation and properties of 1-hydroxycarboranes. Bull. Acad. Sci. USSR, Div. Chem. Sci. 1970, 2153-2156.
23. Coult, R.; Fox, M. A.; Gill, W. R.; Herbertson, P. L.; MacBride, J. A. H.; Wade, K. C-Arylation and C-heteroarylation of icosahedral carboranes via their copper(I) derivatives. J. Organometal. Chem. 1993, 462, 19-29.
24. Fox, M. A.; MacBride, J. A. H.; Peace, R. J.; Wade, K. Transmission of electronic effects by icosahedral carboranes; skeletal carbon-13 chemical shifts and ultraviolet-visible spectra of substituted aryl-p-carboranes (1, 12-dicarba-closo-dodecaboranes). J. Chem. Soc., Dalton Trans. 1998, 401-411.
25. Zharov, I.; Saxena, A.; Michl, J.; Miller, R. D. C-Hydroxydicarba-closo- dodecaboranes. Inorg. Chem. 1997, 36, 6033-6038.
26. Ishioka, T.; Kubo, A.; Koiso, Y.; Nagasawa, K.; Itai, A.; Hashimoto, Y. Novel nonsteroidal/nonanilide type androgen antagonists with an isoxazolone moiety. Bioorg. Med. Chem. 2002, 10, 1555-1566.
27. 3H]DHT was enough to saturate the binding site in the hAR ligand binding domain. All binding data indicate the mean values of the two isolated assays.
28. Kitamura, S.; Suzuki, T.; Ohta, S.; Fujimoto, N. Antiandrogenic activity and metabolism of the organophosphorus pesticide fenthion and related compounds. Environ. Health Perspect. 2003, 111, 503-8.
29. Hiraoka, D.; Nakamura, N.; Nishizawa, Y.; Uchida, N.; Noguchi, S.; Matsumoto, K.; Sato, B. Inhibitory and stimulatory effects of glucocorticoid on androgen-induced growth of murine Shionogi carcinoma 115 in vivo and in cell culture. Cancer Res. 1987, 47, 6560-6564.
30. Kasayama, S.; Saito, H.; Kouhara, H.; Sumitani, S.; Sato, B. Suramin interrupts androgen-inducible autocrine loop involving heparin binding growth factor in mouse mammary cancer (Shionogi carcinoma 115) cells. J. Cell. Physiol. 1993, 154, 254-261.
31. Tyrrell, C. J.; Denis, L.; Newling, D.; Soloway, M.; Channer, K.; Cockshott, I. D. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacoldnetics from three Phase II dose-ranging studies. Eur. Urol. 1998, 9, 39-53.
32. Tucker, H.; Crook, J. W.; Chesterson, G. J. Nonsteroidal anti-androgens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. J. Med. Chem. 1988, 31, 954-959.
33. Morris, J. J.; Hughes, L. R.; Glen, A. T.; Taylor, P. J. Nonsteroidal antiandrogens. Design of novel compounds based on an infrared study of the dominant conformation and hydrogen-bonding properties of a series of anilide antiandrogens. J. Med. Chem. 1991, 34, 447-455.
34. Marhefka, C. A.; Gao, W.; Chung, K.; Kim, J.; He, Y.; Yin, D.; Bohl, C.; Dalton, J. T.; Miller, D. D. Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J. Med. Chem. 2004, 47, 993-998.